Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Small Intestinal Carcinoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(37)
News
Trials
VERI cancer hierarchy
x
x
x
x
Reset Filters
MSI-H/dMMR
Small Intestinal Carcinoma
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive: A1 - Approval
NICE - 1 week (New A2)
pembrolizumab
Sensitive
:
A1
NICE - 1wk
pembrolizumab
Sensitive: A1 - Approval
NICE - 1 week
pembrolizumab
Sensitive
:
A1
NICE - 1 week - (New A2)
NTRK3 fusion
Small Intestinal Carcinoma
NTRK3 fusion
Small Intestinal Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
gemcitabine + docetaxel
Sensitive: A2 - Guideline
gemcitabine + docetaxel
Sensitive
:
A2
gemcitabine + docetaxel
Sensitive: A2 - Guideline
gemcitabine + docetaxel
Sensitive
:
A2
NTRK1 fusion
Small Intestinal Carcinoma
NTRK1 fusion
Small Intestinal Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Small Intestinal Carcinoma
NTRK2 fusion
Small Intestinal Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
gemcitabine + albumin-bound paclitaxel
Sensitive: A2 - Guideline
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
LV5FU2
Sensitive: A2 - Guideline
LV5FU2
Sensitive
:
A2
LV5FU2
Sensitive: A2 - Guideline
LV5FU2
Sensitive
:
A2
MSI-H/dMMR
Small Intestinal Carcinoma
MSI-H/dMMR
Small Intestinal Carcinoma
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
MSI-H/dMMR
Small Intestinal Carcinoma
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab + ipilimumab
Sensitive: A2 - Guideline
pembrolizumab + ipilimumab
Sensitive
:
A2
pembrolizumab + ipilimumab
Sensitive: A2 - Guideline
pembrolizumab + ipilimumab
Sensitive
:
A2
MSI-H/dMMR
Small Intestinal Carcinoma
MSI-H/dMMR
Small Intestinal Carcinoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
FOLFOX
Sensitive: A2 - Guideline
FOLFOX
Sensitive
:
A2
FOLFOX
Sensitive: A2 - Guideline
FOLFOX
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
bevacizumab
Sensitive: A2 - Guideline
bevacizumab
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
capecitabine
Sensitive: A2 - Guideline
capecitabine
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
irinotecan
Sensitive: A2 - Guideline
irinotecan
Sensitive
:
A2
irinotecan
Sensitive: A2 - Guideline
irinotecan
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
FOLFIRI
Sensitive: A2 - Guideline
FOLFIRI
Sensitive
:
A2
FOLFIRI
Sensitive: A2 - Guideline
FOLFIRI
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
albumin-bound paclitaxel
Sensitive: A2 - Guideline
albumin-bound paclitaxel
Sensitive
:
A2
albumin-bound paclitaxel
Sensitive: A2 - Guideline
albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
paclitaxel + gemcitabine
Sensitive: A2 - Guideline
paclitaxel + gemcitabine
Sensitive
:
A2
paclitaxel + gemcitabine
Sensitive: A2 - Guideline
paclitaxel + gemcitabine
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
carboplatin + paclitaxel
Sensitive: A2 - Guideline
carboplatin + paclitaxel
Sensitive
:
A2
carboplatin + paclitaxel
Sensitive: A2 - Guideline
carboplatin + paclitaxel
Sensitive
:
A2
NTRK1 fusion
Small Intestinal Carcinoma
NTRK1 fusion
Small Intestinal Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Small Intestinal Carcinoma
NTRK2 fusion
Small Intestinal Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Small Intestinal Carcinoma
NTRK3 fusion
Small Intestinal Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
GTX
Sensitive: A2 - Guideline
GTX
Sensitive
:
A2
GTX
Sensitive: A2 - Guideline
GTX
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
FOLFIRINOX
Sensitive: A2 - Guideline
FOLFIRINOX
Sensitive
:
A2
FOLFIRINOX
Sensitive: A2 - Guideline
FOLFIRINOX
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
mFOLFOX6
Sensitive: A2 - Guideline
mFOLFOX6
Sensitive
:
A2
mFOLFOX6
Sensitive: A2 - Guideline
mFOLFOX6
Sensitive
:
A2
MSI-L/dMMR
Small Intestinal Carcinoma
MSI-L/dMMR
Small Intestinal Carcinoma
dostarlimab-gxly
Sensitive: A2 - Guideline
dostarlimab-gxly
Sensitive
:
A2
dostarlimab-gxly
Sensitive: A2 - Guideline
dostarlimab-gxly
Sensitive
:
A2
RET fusion
Small Intestinal Carcinoma
RET fusion
Small Intestinal Carcinoma
selpercatinib
Sensitive: C1 - Off-label
selpercatinib
Sensitive
:
C1
selpercatinib
Sensitive: C1 - Off-label
selpercatinib
Sensitive
:
C1
BRAF V600E
Small Intestinal Carcinoma
BRAF V600E
Small Intestinal Carcinoma
trametinib + dabrafenib
Sensitive: C1 - Off-label
trametinib + dabrafenib
Sensitive
:
C1
trametinib + dabrafenib
Sensitive: C1 - Off-label
trametinib + dabrafenib
Sensitive
:
C1
PTEN mutation + MSI-H/dMMR
Small Intestinal Carcinoma
PTEN mutation + MSI-H/dMMR
Small Intestinal Carcinoma
PD1 inhibitor
Resistant: C3 – Early Trials
PD1 inhibitor
Resistant
:
C3
PD1 inhibitor
Resistant: C3 – Early Trials
PD1 inhibitor
Resistant
:
C3
MSI-H/dMMR + TMB-L
Small Intestinal Carcinoma
MSI-H/dMMR + TMB-L
Small Intestinal Carcinoma
PD1 inhibitor
Resistant: C3 – Early Trials
PD1 inhibitor
Resistant
:
C3
PD1 inhibitor
Resistant: C3 – Early Trials
PD1 inhibitor
Resistant
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login